Genmab A/S (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
Separately, JPMorgan Chase & Co. assumed coverage on shares of Genmab A/S in a research report on Tuesday, June 21st. They issued a “neutral” rating for the company.
Genmab A/S (OTCMKTS:GNMSF) opened at 158.25 on Tuesday. The company has a market capitalization of $9.47 billion, a price-to-earnings ratio of 94.70 and a beta of 0.75. The stock has a 50 day moving average price of $161.51 and a 200 day moving average price of $161.76. Genmab A/S has a 52-week low of $93.25 and a 52-week high of $183.00.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.